IMM.L Live signals | Maximize Profits with Getagraph.com

Live Chart Being Loaded With Signals

Commentary (19 Apr 2024 @ 11:05):

Stats
Today's Volume	1.32M
Average Volume	2.99M
Market Cap	9.33M
EPS	£0 ( 2023-08-31 )
Next earnings date	( £0 ) 2024-05-08
Last Dividend	£300.00 ( 2021-12-14 )
Next Dividend	£0 ( N/A )
P/E	-2.35
ATR14	£0.0470 (2.04%)

ImmuPharma PLC Correlation

10 Most Positive Correlations

10 Most Negative Correlations

Did You Know?

Correlation is a statistical measure that describes the relationship between two variables. It ranges from -1 to 1, where -1 indicates a perfect negative correlation (as one variable increases, the other decreases), 1 indicates a perfect positive correlation (as one variable increases, the other increases), and 0 indicates no correlation (there is no relationship between the variables).

Correlation can be used to analyze the relationship between any two variables, not just stocks. It's commonly used in fields such as finance, economics, psychology, and more.

ImmuPharma PLC Financials

Annual	2022
Revenue:	£0
Gross Profit:	£-117 563 (0.00 %)
EPS:	£-0.0126

Q2	2023
Revenue:	£69 959.00
Gross Profit:	£11 172.00 (15.97 %)
EPS:	£-0.00250

Q1	2023
Revenue:	£34 980.00
Gross Profit:	£34 980.00 (100.00 %)
EPS:	£-0.00130

Q4	2022
Revenue:	£0
Gross Profit:	£-80 351.00 (0.00 %)
EPS:	£-0.00670

Financial Reports:

No articles found.

ImmuPharma PLC Dividends

(Q3/22)	(Q4/22)	(Q1/23)	(Q2/23)	(Q3/23)	(Q4/23)	(Q1/24)	(Q2/24)	(Q3/24)	(Q4/24)
£0 (N/A)	£0 (N/A)	£0 (N/A)	£0 (N/A)	£0 (N/A)	£0 (N/A)	£0 (N/A)	£0 (N/A)	£0 (N/A)	£0 (N/A)

ImmuPharma PLC Dividend Information - Ex Dividend Knight

Dividend Sustainability Score: 0 - low (50.00%) | Divividend Growth Potential Score: 0 - No dividend growth expected in the near future

Information

First Dividend	£300.00	2021-12-14
Last Dividend	£300.00	2021-12-14
Next Dividend	£0	N/A
Payout Date	0000-00-00
Next Payout Date	N/A
# dividends	1	--
Total Paid Out	£300.00	--
Avg. Dividend % Per Year	240.00%	--
Score	4.01	--
Div. Sustainability Score	0
Div.Growth Potential Score	0
Div. Directional Score	0	--

Next Divdend (Est)
(2024-04-20)

£0 Estimate 0.00 %

Dividend Stability

0.02 Very Bad

Dividend Score

4.01

Pay Frequency

Insufficient data to determine frequency

Yearly Payout

Year	Amount	Yield
2021	£300.00	2 400.00%
2022	£0	0.00%
2023	£0	0.00%
2024	£0	0.00%

Dividend Commentary

The company does not currently pay dividends. Given its current dividend status and a low Dividend Growth Potential Score (DGPS), there's minimal likelihood of dividends being initiated soon. Considering all factors, the near-term dividend outlook for the company remains unpromising.

Top 10 dividend Companies for LSE

Symbol	Title	Last dividend	Frequency	Years Dividend	Yearly Dividend
CGT.L	Dividend Junior	2023-06-01	Annually	44	0.66%
QXT.L	Ex Dividend Junior	2023-07-27	Sporadic	11	0.46%
GOOD.L	Dividend Knight	2023-09-28	Annually	13	0.55%
ARC.L	Ex Dividend Knight	2023-10-05	Annually	8	1.10%
TPFG.L	Dividend Knight	2023-09-21	Annually	11	3.16%
MCT.L	Dividend King	2023-07-13	Quarterly	11	195.14%
CTEC.L	Dividend Knight	2023-08-17	Semi-Annually	8	1.46%
RUR.L	Dividend Knight	2023-06-22	Sporadic	20	10.67%
HSS.L	Dividend Knight	2023-06-08	Sporadic	10	1.00%
BERI.L	Dividend Knight	2023-09-28	Quarterly	19	2.36%

Dividend Sustainability Score (DSS)

Ratio	Actual Value	Weight	Normalized Value	Score	Range
netProfitMarginTTM	-32.54	1.500	-10.00	-10.00	[0 - 0.5]
returnOnAssetsTTM	-1.038	1.200	-10.00	-10.00	[0 - 0.3]
returnOnEquityTTM	0.356	1.500	7.15	10.00	[0.1 - 1]
payoutRatioTTM	0	-1.000	0	0	[0 - 1]
currentRatioTTM	1.169	0.800	9.15	7.32	[1 - 3]
quickRatioTTM	0.970	0.800	9.00	7.20	[0.8 - 2.5]
cashRatioTTM	0.136	1.500	-0.357	-0.535	[0.2 - 2]
debtRatioTTM	0	-1.500	0	0	[0 - 0.6]
interestCoverageTTM	-2.58	1.000	-2.07	-2.07	[3 - 30]
operatingCashFlowPerShareTTM	-0.00502	2.00	-0.00167	-0.00334	[0 - 30]
freeCashFlowPerShareTTM	-0.00533	2.00	-0.00267	-0.00533	[0 - 20]
debtEquityRatioTTM	0	-1.500	0	0	[0 - 2.5]
grossProfitMarginTTM	-0.326	1.000	-8.76	-8.76	[0.2 - 0.8]
operatingProfitMarginTTM	-31.51	1.000	-10.00	-10.00	[0.1 - 0.6]
cashFlowToDebtRatioTTM	0	1.000	-1.111	-1.111	[0.2 - 2]
assetTurnoverTTM	0.0319	0.800	-3.12	-2.50	[0.5 - 2]
Total Score				-2.45

Dividend Growth Score (DGS)

Ratio	Actual Value	Weight	Normalized Value	Score	Range
peRatioTTM	-2.34	1.000	-0.338	0	[1 - 100]
returnOnEquityTTM	0.356	2.50	8.17	10.00	[0.1 - 1.5]
freeCashFlowPerShareTTM	-0.00533	2.00	-0.00178	-0.00533	[0 - 30]
dividendYielPercentageTTM	0	1.500	0	0	[0 - 0.4]
operatingCashFlowPerShareTTM	-0.00502	2.00	-0.00167	-0.00334	[0 - 30]
payoutRatioTTM	0	1.500	0	0	[0 - 1]
pegRatioTTM	-0.949	1.500	-9.66	0	[0.5 - 2]
operatingCashFlowSalesRatioTTM	-15.93	1.000	-10.00	0	[0.1 - 0.5]
Total Score				-1.034

ImmuPharma PLC

ImmuPharma plc, a biopharmaceutical company, discovers and develops peptide-based therapeutics. Its peptide-based therapeutics are used in the therapy areas of autoimmunity and inflammation, and anti-infectives. The company's lead product candidate is the Lupuzor, an autophagy immunomodulator, which is in Phase III clinical trial for the treatment of lupus, an autoimmune chronic inflammatory disease. Its other product candidates include BioAMB, a peptide-based drug for the treatment of Amphotericin-B formulations, a fungal infection caused by the aspergillus family of fungi; and BioCin, a peptide-based antibacterial drug used in high medical need cases and in last line of defense. The company has a collaboration arrangement with Centre National de la Recherche Scientifique for the development of a peptide technology platform for treating diabetes with glucagon-like peptide -1 agonists, as well as development of peptides as glucagon antagonists to treat type I and type II diabetes; and license and development agreement with Avion Pharmaceuticals LLC. ImmuPharma plc was founded in 1999 and is headquartered in London, the United Kingdom.